藥明康德(02359.HK)擬認購300萬英鎊私募基金份額
格隆匯1月10日丨藥明康德(02359.HK)發佈公告,2020年1月10日,公司全資子企業WuXi PharmaTech Healthcare Fund I L.P.(以下簡稱“WuXi Fund I”)與Epidarex Capital Management LLP(以下簡稱“管理人”)簽署Subscription Agreement(以下簡稱“認購協議”),約定由WuXi Fund I認繳Epidarex Capital III UK, LP(以下簡稱“投資基金”或“Epidarex”)的300萬英鎊的份額,其中包括43.27英鎊的股權級份額和2,999,956.73英鎊的債權級份額,約佔已募集投資基金份額的3.0%。截至該公告日,WuXi Fund I尚未支付投資款,後續WuXi Fund I將以自有資金根據合夥協議的要求履行投資款的支付義務。
公告表示,Epidarex 的投資將主要針對英國診療和醫療器械等領域的早期生命科學企業,公司認為其管理團隊在投資市場所積累的豐富經驗和廣泛聯繫使其有能力和機會識別該領域的高質量創新成果,並通過投資幫助此類早期企業獲得資金以加速其創新成果的商業化。公司以較低比例投資 Epidarex 作為其有限合夥人,一方面有望使公司在投資風險可控的前提下,獲得風險投資相關的財務收益。
另一方面,Epidarex 投資所針對的早期生命科學企業是公司重要的潛在客户羣體,同時公司認為以精準醫療為趨勢的創新型診斷、治療技術的研發和應用將是未來全球大健康市場的重要發展機會。該項投資還可以增進公司對新型診斷、治療技術領域發展最新動態理解,支持公司的業務拓展和抓住大健康產業的前沿發展機會。公司在保證日常經營發展所需資金的前提下,以自有資金參與認繳投資基金份額,次投資不會對公司財務狀況和經營成果產生重大影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.